|
|
中医药联合其他疗法治疗原发性肝癌的研究现状
|
Abstract:
原发性肝癌目前仍是全球的重要癌症之一，仍对人类健康有严重威胁，目前已经有许多研究证实中医药在对于肝癌的治疗中有着独特的优势。如今，中西医结合治疗原发性肝癌已经是大势所趋。通过探索相关中医证候和中医药对原发性肝癌中医药治疗联合其他治疗的临床研究，探讨分析当今中医药联合手术、消融、TACE、靶向、免疫治疗原发性肝癌的临床疗效和安全性，并对其进行综合性分析。最终发现在西医治疗的基础上联合中医药治疗能够在提高患者的临床疗效、延长患者生存率、减少肿瘤复发概率、缓解不良反应等方面都发挥了重要作用。
Primary liver cancer is still one of the important cancers worldwide at present and still poses a serious threat to human health. At present, many studies have confirmed that traditional Chinese medicine has unique advantages in the treatment of liver cancer. Nowadays, the combination of traditional Chinese and Western medicine in the treatment of primary liver cancer has become a general trend. By exploring relevant traditional Chinese medicine syndromes and clinical studies on the combination of traditional Chinese medicine and other treatments in the treatment of primary liver cancer, exploring and analyzing the clinical efficacy and safety of traditional Chinese medicine combined with surgery, ablation, TACE, targeted and immunotherapy in the treatment of primary liver cancer at present, and conducting comprehensive analysis, eventually, it is found that on the basis of Western medicine treatment, the combination of traditional Chinese medicine treatment can play an important role in improving the clinical efficacy of patients, prolonging the survival rate of patients, reducing the probability of tumor recurrence, and alleviating adverse reactions.
| [1] | Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. https://doi.org/10.3322/caac.21660 |
| [2] | 宋天强. 肝癌新辅助治疗的焦点与未来[J]. 中国实用外科杂志, 2023, 43(3): 281-285. |
| [3] | 王荟荟, 李惠, 张延英, 等. 中医药辅助癌症免疫治疗的研究进展[J]. 中国比较医学杂志, 2023, 33(3): 130-135. |
| [4] | 黄婉婷, 郭涛, 张晶, 等. 原发性肝癌气滞血瘀证的研究进展[J]. 世界科学技术-中医药现代化, 2023, 25(11): 3724-3727. |
| [5] | 吴宇. 血府逐瘀汤治疗气滞血瘀型原发性肝癌TACE术后栓塞综合征的临床疗效观察[D]: [硕士学位论文]. 成都: 成都中医药大学, 2024. |
| [6] | 姬佳琦, 胡校庆, 赵艺涵, 等. 血府逐瘀汤在恶性肿瘤疾病中的研究进展[J/OL]. 中国实验方剂学杂志, 1-14. https://doi.org/10.13422/j.cnki.syfjx.20250623, 2025-03-22. |
| [7] | Peng, Y., Wu, X., Zhang, Y., Yin, Y., Chen, X., Zheng, D., et al. (2023) An Overview of Traditional Chinese Medicine in the Treatment after Radical Resection of Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 10, 2305-2321. https://doi.org/10.2147/jhc.s413996 |
| [8] | Chen, Q., Shu, C., Laurence, A.D., et al. (2018) Effect of Huaier Granule on Recurrence after Curative Resection of HCC: A Multicentre, Randomised Clinical Trial. Gut, 67, 2006-2016. |
| [9] | 陈虹宇, 甄宏德, 周瑞生, 等. 中医治疗对原发性肝癌术后复发及生存时间的影响[J]. 中医肿瘤学杂志, 2023, 5(5): 18-24. |
| [10] | 温旭东, 潘涛, 陈柳霖, 等. “补气生血法”促肝切除术后肝再生理论初探[J]. 成都中医药大学学报, 2023, 46(1): 14-18. |
| [11] | 史瑶平, 孟志强, 翟博. 复合式冷热消融系统治疗原发性肝癌中国专家共识(2023) [J]. 临床肝胆病杂志, 2023, 39(12): 2793-2797. |
| [12] | Kong, Y., Zhu, X., Zhang, X., Li, Z., Yin, Y., Wang, J., et al. (2023) Traditional Chinese Medicine Combined with Radiofrequency Ablation Improves Primary Liver Cancer Outcomes: A Systematic Review with Meta-Analysis. Heliyon, 9, e18591. https://doi.org/10.1016/j.heliyon.2023.e18591 |
| [13] | 刘鹏, 陈青山, 杨建波. 柴胡疏肝散加减联合射频消融治疗肝癌疗效研究[J]. 陕西中医, 2023, 44(7): 892-896. |
| [14] | 黄玉迎, 杨培伟, 周铖, 等. 针灸对肝癌射频消融术后免疫功能改善研究进展[J]. 辽宁中医药大学学报, 2024, 26(3): 104-109. |
| [15] | 吴巧红, 黄旭芳, 毛剑婷, 等. 耳穴贴压对肝癌射频消融患者超前镇痛干预的应用效果研究[J]. 介入放射学杂志, 2020, 29(10): 1047-1051. |
| [16] | 中国医师协会肝癌专业委员会. 肝细胞癌分子靶向药物临床应用中国专家共识(2022版) [J]. 中华医学杂志, 2022, 102(34): 2655-2668. |
| [17] | 石功亮, 何勇, 颜艳倩. 槐耳颗粒联合分子靶向药物治疗脾虚型原发性肝癌的临床疗效[J]. 西部医学, 2024, 36(1): 120-124. |
| [18] | Yang, Y., Sun, M., Yao, W., Wang, F., Li, X., Wang, W., et al. (2020) Compound Kushen Injection Relieves Tumor-Associated Macrophage-Mediated Immunosuppression through TNFR1 and Sensitizes Hepatocellular Carcinoma to Sorafenib. Journal for ImmunoTherapy of Cancer, 8, e000317. https://doi.org/10.1136/jitc-2019-000317 |
| [19] | Zhao, H., Meng, Y., Zhai, X., Cheng, B., Yu, S., Yao, M., et al. (2020) Comparable Effects of Jiedu Granule, a Compound Chinese Herbal Medicine, and Sorafenib for Advanced Hepatocellular Carcinoma: A Prospective Multicenter Cohort Study. Journal of Integrative Medicine, 18, 319-325. https://doi.org/10.1016/j.joim.2020.05.003 |
| [20] | 中国医师协会肝癌专业委员会. 肝细胞癌免疫治疗中国专家共识(2021版) [J]. 中华医学杂志, 2021, 101(48): 3921-3931. |
| [21] | 喻丹, 何胜利, 沈婕, 等. 如意金黄散联合ICIs治疗肝癌晚期伴肝胆湿热证者的临床观察[J]. 中国药房, 2023, 34(12): 1488-1492. |
| [22] | 徐森华, 吴蕾. 穴位敷贴改善原发性肝癌患者肝功能和凝血功能的研究[J]. 现代肿瘤医学, 2022, 30(23): 4313-4317. |
| [23] | 雍金鹏, 周世繁, 周超锋, 等. 康莱特注射液联合靶向治疗和免疫治疗对中晚期肝癌患者疗效的评价[J]. 实用中西医结合临床, 2023, 23(22): 61-63+83. |
| [24] | Chen, R., Chen, L., Wang, C., Zhu, H., Gu, L., Li, Y., et al. (2023) CAR-T Treatment for Cancer: Prospects and Challenges. Frontiers in Oncology, 13, Article 1288383. https://doi.org/10.3389/fonc.2023.1288383 |
| [25] | Liu, J., Tu, X., Liu, L. and Fang, W. (2022) Advances in CAR-T Cell Therapy for Malignant Solid Tumors. Journal of Zhejiang University (Medical Sciences), 51, 175-184. https://doi.org/10.3724/zdxbyxb-2022-0044 |
| [26] | Chohan, K.L., Siegler, E.L. and Kenderian, S.S. (2023) CAR-T Cell Therapy: The Efficacy and Toxicity Balance. Current Hematologic Malignancy Reports, 18, 9-18. https://doi.org/10.1007/s11899-023-00687-7 |
| [27] | 石磊, 顾瞻, 张慧卿. CAR-T治疗相关不良反应的中医病因病机及治法[J]. 临床与病理杂志, 2023, 43(9): 1713-1719. |
| [28] | Lencioni, R., de Baere, T., Soulen, M.C., Rilling, W.S. and Geschwind, J.H. (2016) Lipiodol Transarterial Chemoembolization for Hepatocellular Carcinoma: A Systematic Review of Efficacy and Safety Data. Hepatology, 64, 106-116. https://doi.org/10.1002/hep.28453 |
| [29] | 中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗指南(2022年版) [J]. 肿瘤综合治疗电子杂志, 2022(8): 16-53. |
| [30] | 陈晓琦, 张鹏鸽, 陈新蕊, 等. 扶正消瘤颗粒对原发性肝癌血清中VEGF、HIF-1α表达的影响及临床意义[J]. 世界科学技术-中医药现代化, 2020, 22(10): 3629-3635. |
| [31] | 赵容, 李静, 严涵, 等. 柴胡化积方对原发性肝癌TACE术后综合征外周血炎症因子及bFGF、MMP-9、VEGF水平的影响[J]. 湖南中医药大学学报, 2023, 43(12): 2328-2334. |
| [32] | 燕彩霞, 王达, 魏传霞, 等. 酸味方对原发性肝癌经导管肝动脉化疗栓塞术后血清AFP、CEA、CA-125及CD+4/CD+8水平的影响[J]. 中华中医药学刊, 2024, 42(8): 98-102. |
| [33] | Zhao, R., Wang, L., Liu, Y., Shao, M., Yang, W., Fu, Y., et al. (2023) The Influence of Adjunctive Traditional Chinese Medicine Therapy on Survival in Primary Liver Cancer: A Real-World Study Based on Electronic Medical Records. Frontiers in Pharmacology, 14, Article 1231933. https://doi.org/10.3389/fphar.2023.1231933 |
| [34] | Zhang, Z., Li, J., Zeng, P., Gao, W. and Tian, X. (2022) Data Mining and Systems Pharmacology to Elucidate Effectiveness and Mechanisms of Chinese Medicine in Treating Primary Liver Cancer. Chinese Journal of Integrative Medicine, 28, 636-643. https://doi.org/10.1007/s11655-021-3449-8 |
